Tag: chronic lymphocytic leukemia

Zanubrutinib Better Than Ibrutinib in CLL/SLL?

Zanubrutinib (Brukinsa), a second-generation Bruton tyrosine kinase (BTK) inhibitor, has shown a significantly greater delay in disease progression vs the standard of care ibrutinib (Imbruvica)...

Ublituximab Plus Ibrutinib for CLL

Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease associated with several known genetic abnormalities, including 17p deletion (del[17p]), 11q deletion (del[11q]), and TP53 gene...

Experts Offer Roadmap for Treating CLL During the Pandemic

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. COVID-19 has thrown a wrench in standard treatment protocols for patients...

FDA OKs Ofatumumab (Kesimpta) for Relapsing Forms of MS

The US Food and Drug Administration (FDA) has approved ofatumumab injection (Kesimpta, Novartis) for the treatment of adults with relapsing forms of multiple sclerosis, including...

Ofatumumab Phase 3 Multiple Sclerosis Trials Published

Two phase 3 clinical trials showing impressive results with the new subcutaneously-delivered, B-cell depleting multiple sclerosis anti-CD20 mononclonal antibody ofatumumab (Arzerra) have now been published...

Ofatumumab Shows High Elimination of Disease Activity in MS

With ofatumumab (Arzerra, Novartis), a fully human anti-CD20 monoclonal antibody, there is a greater likelihood of there being no evidence of disease activity (NEDA-3) for...

Think Before Referring Lymphocytocis Patients, Urge UK Docs

Patients with asymptomatic lymphocytosis should not be referred to a haematology clinic unless they have a white cell count above a certain threshold, to avoid...